(PRME) Prime Medicine, Common Stock - Ratings and Ratios
Gene Editing, Prime Editor, PegRNA, Cell Shielding, Immunotherapy
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 93.4% |
| Value at Risk 5%th | 145% |
| Relative Tail Risk | -5.93% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.71 |
| Alpha | -6.98 |
| CAGR/Max DD | -0.45 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.551 |
| Beta | 1.908 |
| Beta Downside | 2.142 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.55% |
| Mean DD | 66.12% |
| Median DD | 73.52% |
Description: PRME Prime Medicine, Common Stock December 30, 2025
Prime Medicine, Inc. (NASDAQ: PRME) is a Cambridge-based biotech that commercializes its proprietary “Prime Editing” platform-a CRISPR-derived, single-turnover gene-editing system that inserts precise DNA changes without inducing double-stranded breaks. The technology combines a catalytically-improved Cas9 nickase, a reverse-transcriptase (RT) domain, and a pegRNA that both locates the target site and encodes the desired edit. Prime Medicine’s current focus is on partnership-driven programs, most notably a research collaboration with Cimeio Therapeutics to create “Prime-Edited Shielded-Cell & Immunotherapy” pairs for genetic diseases, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). The company was incorporated in 2019 and trades as a common stock in the U.S. biotechnology sub-industry.
As of the most recent 10-Q (Q3 2024), PRME reported cash and cash equivalents of roughly $150 million, a monthly cash burn of ≈ $12 million (≈ $144 million annualized), and R&D spending representing 68 % of total operating expenses-typical for early-stage gene-editing firms. The market capitalization hovered around $550 million, implying a price-to-sales multiple of ~ 30× based on projected 2025 revenue from anticipated licensing deals and early-stage therapeutic milestones. These metrics suggest the company is still runway-constrained and highly dependent on successful pre-clinical data to unlock partnership funding.
The broader gene-editing sector is being driven by three macro forces: (1) a projected CAGR of ~ 15 % through 2030 for the global gene-therapy market (≈ $15 billion by 2030), (2) increasing FDA comfort with non-viral, precise editing approaches after the approval of base-editing therapies, and (3) escalating venture and strategic capital inflows-U.S. biotech IPO proceeds reached a 5-year high of $12 billion in 2023, providing a favorable fundraising environment for companies like Prime Medicine.
For a deeper, data-rich view of PRME’s valuation dynamics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-197.3m TTM) > 0 and > 6% of Revenue (6% = 358.6k TTM) |
| FCFTA -0.30 (>2.0%) and ΔFCFTA 27.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3286 % (prev 324.0%; Δ 2962 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.28 (>3.0%) and CFO -109.1m > Net Income -197.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (160.5m) change vs 12m ago 34.02% (target <= -2.0% for YES) |
| Gross Margin -724.3% (prev 91.20%; Δ -815.5pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.67% (prev 19.31%; Δ -17.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -62.02 (EBITDA TTM -193.4m / Interest Expense TTM -3.23m) >= 6 (WARN >= 3) |
Altman Z'' -11.50
| (A) 0.51 = (Total Current Assets 231.4m - Total Current Liabilities 35.0m) / Total Assets 385.0m |
| (B) -2.19 = Retained Earnings (Balance) -842.3m / Total Assets 385.0m |
| warn (B) unusual magnitude: -2.19 — check mapping/units |
| (C) -0.56 = EBIT TTM -200.6m / Avg Total Assets 358.9m |
| (D) -3.77 = Book Value of Equity -842.2m / Total Liabilities 223.2m |
| Total Rating: -11.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.64
| 1. Piotroski 0.0pt |
| 2. FCF Yield -20.77% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.73 |
| 5. Debt/Ebitda -0.24 |
| 7. RoE -163.5% |
| 8. Rev. Trend 33.24% |
| 9. EPS Trend 18.11% |
What is the price of PRME shares?
Over the past week, the price has changed by -0.86%, over one month by -0.86%, over three months by -37.92% and over the past year by +16.05%.
Is PRME a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PRME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.4 | 84.7% |
| Analysts Target Price | 6.4 | 84.7% |
| ValueRay Target Price | 2.9 | -16.4% |
PRME Fundamental Data Overview December 27, 2025
P/S = 107.8171
P/B = 3.9823
Beta = 2.709
Revenue TTM = 5.98m USD
EBIT TTM = -200.6m USD
EBITDA TTM = -193.4m USD
Long Term Debt = 118.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.71m USD (from shortTermDebt, last quarter)
Debt = 118.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 46.7m USD (from netDebt column, last quarter)
Enterprise Value = 554.1m USD (644.4m + Debt 118.1m - CCE 208.4m)
Interest Coverage Ratio = -62.02 (Ebit TTM -200.6m / Interest Expense TTM -3.23m)
FCF Yield = -20.77% (FCF TTM -115.1m / Enterprise Value 554.1m)
FCF Margin = -1926 % (FCF TTM -115.1m / Revenue TTM 5.98m)
Net Margin = -3302 % (Net Income TTM -197.3m / Revenue TTM 5.98m)
Gross Margin = -724.3% ((Revenue TTM 5.98m - Cost of Revenue TTM 49.3m) / Revenue TTM)
Gross Margin QoQ = -3491 % (prev -67.17%)
Tobins Q-Ratio = 1.44 (Enterprise Value 554.1m / Total Assets 385.0m)
Interest Expense / Debt = 0.37% (Interest Expense 434.0k / Debt 118.1m)
Taxrate = -0.0% (0.0 / -195.9m)
NOPAT = -200.6m (EBIT -200.6m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 6.61 (Total Current Assets 231.4m / Total Current Liabilities 35.0m)
Debt / Equity = 0.73 (Debt 118.1m / totalStockholderEquity, last quarter 161.8m)
Debt / EBITDA = -0.24 (negative EBITDA) (Net Debt 46.7m / EBITDA -193.4m)
Debt / FCF = -0.41 (negative FCF - burning cash) (Net Debt 46.7m / FCF TTM -115.1m)
Total Stockholder Equity = 120.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.26% (Net Income -197.3m / Total Assets 385.0m)
RoE = -163.5% (Net Income TTM -197.3m / Total Stockholder Equity 120.7m)
RoCE = -83.98% (EBIT -200.6m / Capital Employed (Equity 120.7m + L.T.Debt 118.1m))
RoIC = -166.2% (out of range, set to none) (NOPAT -200.6m / Invested Capital 120.7m)
WACC = 11.09% (E(644.4m)/V(762.6m) * Re(13.05%) + D(118.1m)/V(762.6m) * Rd(0.37%) * (1-Tc(-0.0)))
Discount Rate = 13.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.38%
Fair Price DCF = unknown (Cash Flow -115.1m)
EPS Correlation: 18.11 | EPS CAGR: -4.53% | SUE: 0.97 | # QB: 1
Revenue Correlation: 33.24 | Revenue CAGR: 151.2% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.24 | Chg30d=-0.006 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.90 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+29.8% | Growth Revenue=+205.9%
Additional Sources for PRME Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle